FUNCTIONAL METHODS FOR QUANTIFYING AGONISTS AND ANTAGONISTS

REFERENCES

• Leff P., Dougall I. G. Is pharmacological analysis of agonist action useful in medicinal chemistry?. Trends in Receptor Research, P. Angeli, U. Gulini, W. Quaglia. Elsevier Science Publishers BV, Amsterdam 1992; 43–60
   Google Scholar
• Clark A. J. General pharmacology. Heffter's Handbuch Der Experimentallen Pharmakologie Erganzungswerk. Springer-Verlag, Berlin 1937; 4: 1–223
   Google Scholar
• Arie¨ns E. J. Affinity and intrinsic activity in the theory of competitive inhibition. Arch. Int. Pharmacodyn. Ther. 1954; 99: 32–49
   PubMedGoogle Scholar
• Stephenson R. P. A modification of receptor theory. Br. J. Pharmacol. 1956; 11: 379–393
   PubMed Web of Science ®Google Scholar
• Mackay D. A flux-carrier hypothesis of drug-action. Nature 1963; 197: 1171–1173
   Google Scholar
• Furchgott R. F. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv. Drug Res., N. J. Harper, A. B. Simmonds. Academic Press, New York 1966; 3: 21–55
   Google Scholar
• Paton W. D.M. A theory of drug action based on the rate of drug-receptor combination. Proc. R. Soc. Lond. B 1961; 154: 21–69
   Web of Science ®Google Scholar
• Colquhoun D. The relationship between classical and cooperative models for drug action. Drug Receptors, H. P. Rang. University Park Press, Baltimore 1973; 149–182
   Google Scholar
• Gosselin R. E. Drug-receptor inactivation: a new kinetic model. Kinetics of Drug Action, J. M. Van Rossum. Springer-Verlag, Berlin 1977; 323–356
   Google Scholar
• Ruffolo R. R. Important concepts of receptor theory. J. Autonom Pharmacol. 1982; 2: 277–295
   PubMedGoogle Scholar
• Mackay D. A critical survey of receptor theories of drug action. Kinetics of Drug Action, J. M. Van Rossum. Springer-Verlag, Berlin 1977; 255–322
   Google Scholar
• Black J. W., Leff P. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B 1983; 220: 141–162
   PubMed Web of Science ®Google Scholar
• Leff P. The two-state model of receptor activation. Trends Pharmacol. Sci. 1995; 16: 89–97
   PubMed Web of Science ®Google Scholar
• Leff P., Prentice D. J., Giles H., Martin G. R., Wood J. Estimation of agonist affinity and efficacy by direct operational model fitting. J. Pharmacol. Methods 1990; 23: 225–237
   PubMedGoogle Scholar
• Nickerson M. Receptor occupancy and tissue response. Nature 1956; 178: 697–698
   PubMedGoogle Scholar
• Waud D. R. On the measurement of the affinity of partial agonists for receptors. J. Pharmacol. Exp. Ther. 1969; 170: 117–122
   PubMedGoogle Scholar
• Leff P. Can operational models of agonism provide a framework for classifying hormone receptors?. Perspectives on Receptor Classification, J. W. Black, D. H. Jenkinson, V. P. Gerskowitch. Alan R Liss, New York 1987; 157–167
   Google Scholar
• Black J. W., Left P., Shankley N. P., Wood J. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br. J. Pharmacol. 1985; 84: 561–571
   PubMed Web of Science ®Google Scholar
• Barlow R. B., Scott N. C., Stephenson R. P. The affinity and efficacy of onium salts on frog rectus abdominis. Br. J. Pharmacol. 1967; 31: 188–196
   Google Scholar
• Leff P., Dougall I. G., Harper D. Estimation of partial agonist affinity by interaction with a full agonist: a direct operational model-fitting approach. Br. J. Pharmacol. 1993; 110: 239–244
   PubMedGoogle Scholar
• MacKay D. Concentration-response curves and receptor classification: null method or operational model?. Trends Pharmacol. Sci. 1988; 9: 202–205
   PubMedGoogle Scholar
• Leff P. Analysis of agonist action using the operational model. Trends Pharmacol. Sci. 1988; 9: 395–398
   PubMedGoogle Scholar
• Thron C. D. Graphical and weighted regression analyses for the determination of agonist dissociation constants. J. Pharmacol. Exp. Ther. 1970; 175: 541–553
   PubMedGoogle Scholar
• Parker R. B., Waud D. R. Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists. J. Pharmacol. Exp. Ther. 1971; 177: 1–12
   PubMedGoogle Scholar
• James M. K., Morgan P. H., Leighton H. F. A new method for estimation of agonist dissociation constants (KA); directly fitting the postinactivation concentration-response curve to a nested hyperbolic equation. J. Pharmacol. Exp. Ther. 1989; 249: 61–69
   PubMedGoogle Scholar
• Kramer T. H., Davis P., Hruby V. J., Burks T. F., Porreca F. In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands. J. Pharmacol. Exp. Ther. 1993; 266: 577–584
   PubMedGoogle Scholar
• Wiener L. H., Thalody G. P. Differential attenuation of the responses to adenosine and methoxamine in isolated rabbit aorta. J. Pharmacol. Exp. Ther. 1993; 267: 828–837
   PubMedGoogle Scholar
• Sallés J., Giraldo J., Badia A. Analysis of agonism at functional prejunctional α2-adrenoceptors of rat vas deferens using operational and null approaches. Eur. J. Pharmacol. 1994; 258: 229–238
   PubMedGoogle Scholar
• Palea S., Corsi M., Rimland J. M., Trist D. G. Discrimination by benextramine between the NPY-Y1receptor subtypes present in rabbit isolated vas deferens and saphenous vein. Br. J. Pharmacol. 1995; 115: 3–10
   PubMedGoogle Scholar
• Zernig G., Issaevitch T., Woods J. H. Calculation of agonist efficacy, apparent affinity and receptor population changes after administration of insurmountable antagonists: comparison of different analytical approaches. J. Pharmacol. Toxicol. Methods 1996; 35: 223–237
   PubMedGoogle Scholar
• Zaborowsky B. R., McMahan W. C., Griffin W. A., Norris F. H., Ruffolo R. R. Computerized graphic methods for determining dissociation constants of agonists, partial agonists and competitive antagonists in isolated smooth muscle preparations. J. Pharmacol. Methods 1980; 4: 165–178
   PubMedGoogle Scholar
• McPherson G. A., Molenaar P., Raper C., Malta E. Analysis of dose-response curves and calculation of agonist dissociation constants using a weighted non-linear curve fitting program. J. Pharmacol. Methods 1983; 10: 231–241
   PubMedGoogle Scholar
• Schild H. O. pAx and competitive drug antagonism. Br. J. Pharmacol. 1949; 4: 277–280
   Google Scholar
• Arunlakshana O., Schild H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959; 14: 48–58
   PubMed Web of Science ®Google Scholar
• Kenakin T. P. Pharmacological Analysis of Drug-Receptor Interaction. 2nd Ed., Raven Press, New York 1993
   Google Scholar
• Lemoine H., Kaumann A. J. A model for the interaction of competitive antagonists with two receptor subtypes characterized by a Schild plot with apparent slope unity. Naunyn Schmiedeberg's Arch. Pharmacol. 1983; 322: 111–120
   Google Scholar
• Stone M., Angus J. A. Developments of computer-based estimation of pA2 values and associated analysis. J. Pharmacol. Exp. Ther. 1978; 207: 705–718
   PubMedGoogle Scholar
• Trist D. G., Leff P. Quantification of H2-agonism by clonidine and dimaprit in an adenylate cyclase assay. Agents Actions 1985; 16: 222–226
   PubMedGoogle Scholar
• Lew M. J., Angus J. A. Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol. Sci. 1995; 16: 328–337
   PubMed Web of Science ®Google Scholar
• Dougall I. G., Harper D., Lydford S. J., Leff P., Unpublished
   Google Scholar
• BMDP Statistical Software, W. J. Dixon. University of California Press, Berkeley 1981
   Google Scholar
• Lydford S. J., McKechnie K. C.W., Leff P. Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein. Prostaglandins 1996; 52: 125–139
   PubMedGoogle Scholar
• DeMarinis R. M., Hieble J. P. Dopamine receptor agonists: chemical and biological studies of the aminoethylindolones. Drugs Fut. 1989; 14: 780–797
   Google Scholar